State Street Corp Purchases 79,505 Shares of Cerus Co. (NASDAQ:CERS)

State Street Corp grew its position in shares of Cerus Co. (NASDAQ:CERS) by 2.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,738,893 shares of the biotechnology company’s stock after buying an additional 79,505 shares during the quarter. State Street Corp owned approximately 2.01% of Cerus worth $6,506,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. The Manufacturers Life Insurance Company raised its holdings in shares of Cerus by 10.9% in the second quarter. The Manufacturers Life Insurance Company now owns 73,372 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 7,209 shares during the last quarter. Creative Planning raised its stake in shares of Cerus by 51.3% in the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 8,411 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Cerus by 0.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,754,540 shares of the biotechnology company’s stock worth $3,053,000 after purchasing an additional 8,707 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in shares of Cerus by 38.4% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 35,074 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 9,737 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Cerus by 4.4% during the second quarter. Rhumbline Advisers now owns 252,444 shares of the biotechnology company’s stock valued at $444,000 after purchasing an additional 10,739 shares during the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Insider Buying and Selling

In other news, Director Eric Bjerkholt sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total value of $35,600.00. Following the transaction, the director now directly owns 162,133 shares in the company, valued at $288,596.74. This trade represents a 10.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.40% of the stock is currently owned by insiders.

Cerus Stock Performance

Cerus stock opened at $1.56 on Friday. The company has a market cap of $289.72 million, a PE ratio of -14.18 and a beta of 1.24. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19. Cerus Co. has a 1 year low of $1.38 and a 1 year high of $2.59. The company’s 50-day moving average is $1.72 and its two-hundred day moving average is $1.90.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus dropped their price objective on shares of Cerus from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, October 17th.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.